LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces a class action lawsuit has been filed on behalf of investors in XBiotech, Inc. (“XBiotech” or the “Company”) (NASDAQ: XBIT), concerning possible violations of federal securities laws between April 15, 2015 and November 23, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the February 1, 2016, lead plaintiff motion deadline.
To join this class action lawsuit, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at firstname.lastname@example.org.
According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients for the Phase III Study, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome. When the truth was revealed, shares dropped causing investors harm.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.